Abstract:Title. Androgen Receptor Protein Degraders Patent Publication Number. WO 2020/142228 A1 Publication Date. July 09, 2020 Priority Application. US 62/788,005 Priority Date. January 03, 2019 Inventors.Wang, S.; Han, X.; Wang, C.; Qin, C.; Xiang, W.; Xu, T.; Yang, C. Assignee Company. The Regents of the University of Michigan [US/US]; Office of Technology Transfer, 1600 Huron Parkway, second Floor, Ann Arbor, MI 48109−2590 (US). Disease Area. Prostate cancer (PCa) Biological Target. Androgen receptor Summary. Androgens are a class of steroid hormones that consist of natural or synthetic steroid hormone derivatives of cholesterol, which play a role in the development and maintenance of male characteristics. They function primarily through androgen receptor (AR) signaling and are recognized as a key driver of prostate cancer (PCa) growth and survival. The AR is a 110 kDa protein with sequence homology that is shared with other nuclear hormone receptors in the superfamily such as the progesterone receptor (PR), estrogen receptor (ER), and glucocorticoid receptor (GR). Furthermore, the AR consists of four basic elements: the N-terminal domain, DNA binding domain, hinge region, and ligand binding domain (LBD). The centrally located DNA binding domain consists of two zinc finger domains that recognize a specific DNA sequence and is the most highly conserved region. Whereas, the LBD forms the ligand-binding pocket that contains ligand-dependent activation function 2 (AF-2) and mediates interactions between the AR, heat shock proteins, and motifs located within the N-terminal domain. PCa remains themost common cancer and the second leading cause of cancer-related deaths inmen. However, if detected early the current arsenal of therapeutic options provide a promising chance for long-term survival, though ∼40% of patients will develop castration-resistant PCa. Androgen deprivation therapy (ADT) remains the primary treatment regimen for patients who demonstrate biochemical relapse and those that are challenged with locally advanced or metastatic disease. In some cases, the disease ultimately progresses to a lethal form despite castrating levels of testosterone and is termed metastatic castrationresistant prostate cancer (mCRPC). Most often, mCRPC is characterized by rising serum levels of prostate-specific antigen (PSA) after the restoration of the AR transcriptional activity. Consequently, the standard of care for patients with mCRPC after ADT treatment involves sustained AR inhibition that competitively bind the ligand-binding domain (LBD) of the AR or CYP17A1 inhibitors. Mutation in the AR LBD as well as active AR-splice variants that lack the LBD have been associated with primary and acquired resistance. Consequently, a new therapeutic approach is needed in the treatment of PCa and related diseases associated with the AR. The present Patent Highlight showcases heterobifunctional small molecules that are androgen receptor (AR) protein degraders useful for the treatment of a variety of diseases including prostate cancer. The Proteolysis Targeting Chimera (PROTAC) strategy consists of a heterobifunctional small molecule containing one ligand that binds to the target protein of interest (AR) and a second ligand for an E3 ligase system, tethered together by a chemical linker. Thus, AR degraders designed based upon the PROTAC concept may be effective for the treatment of CRPC when the disease becomes resistant to AR antagonists or to androgen synthesis inhibitors.

Development of 2-(5,6,7-trifluoro-1h-indol-3-yl)-quinoline-5-carboxamide As a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation

Abstract LB133: An orally bioavailable degrader targeting androgen receptor and the splice variant in castration resistant prostate cancer

1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells

A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer

Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer

Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer

Discovery of 2-(1-(3-chloro-4-cyanophenyl)-1h-pyrazol-3-yl)acetamides As Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor

Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain

Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer

Inhibition of Androgen Receptor Nuclear Localization and Castration Resistant Prostate Tumor Growth by Pyrroloimidazole-Based Small Molecules.

Identification of Novel Androgen Receptor Degrading Agents to Treat Advanced Prostate Cancer

Targeting Androgen Receptor Versus Targeting Androgens to Suppress Castration Resistant Prostate Cancer.

Androgen Receptor Protein Degradation in the Treatment of Castration-Resistant Prostate Cancer.

Discovery of Thiohydantoin Based Antagonists of Androgen Receptor with Efficient Degradation for the Treatment of Prostate Cancer

Abstract 7277: Discovery of INV-9956, an orally available and highly selective Cyp11A1 inhibitor for the treatment of castration-resistant prostate cancer with drug resistant AR mutations

Abstract 1001: Functional and Mechanistic Interrogation of Androgen Receptor Degraders for the Treatment of Metastatic Castration Resistant Prostate Cancer

Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer

Discovery of Novel Thiohydantoin Derivatives As Full Antagonists and Efficient Degraders of Androgen Receptor

Developing New Targeting Strategy for Androgen Receptor Variants in Castration Resistant Prostate Cancer